Navigation Links
Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
Date:7/29/2008

s adverse events reported with PBT2.

"These results indicate that PBT2 is having an impact on the underlying biology of Alzheimer's, which is very exciting," Cummings said. "This is a critical proof of concept, and the safety and efficacy demonstrated by PBT2 in this study warrant evaluation in larger scale clinical trials in Alzheimer's."

A Phase IIb trial of a Tau Aggregation Inhibitor Therapy

As an alternative to anti-amyloid therapies for Alzheimer's, researchers continue to examine a variety of treatments and targets with the potential to curb the disease. This includes presenting data supporting the viability of therapies targeting tau protein and its aggregation into the "tangles" originally discovered by Alois Alzheimer.

Previous research has shown that the buildup of brain lesions known as neurofibrillary tangles, which are composed of a short fragment of a protein called tau, is correlated with increasing levels of dementia symptoms. And, these tangles first appear in the brain long before symptoms of the disease become clinically apparent. Methylthioninium chloride (MTC, or brand name rember(TM)) has been shown in the test tube to dissolve tau tangle filaments and prevent aggregation of tau into tangles. MTC has also been shown to block the toxic effects of aggregated tau in cells. In animal models, MTC has demonstrated cognitive and behavioral benefits in line with reduced tau pathology.

In research reported at ICAD 2008, Claude M. Wischik, Professor in Mental Health, University of Aberdeen, United Kingdom and Chairman, TauRx Therapeutics, Singapore, and colleagues conducted a 24-week, double-blind, randomized, dose-ranging, parallel design trial of MTC monotherapy in 321 people with Alzheimer's at 17 centers in the United Kingdom and Singapore, followed by a 60-week, blinded, active treatment extension. The control group received placebo for the initial 24 weeks and then a minimal efficacy dose subsequently. The primar
'/>"/>

SOURCE Alzheimer's Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
5. Controversy About Lack of Placebo Group Decline in Alzheimers Clinical Trials
6. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
7. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
8. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
9. Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
10. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
11. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... has announced the addition of the  "Large ... to their offering.  ,     ... drug delivery market holds significant potential for ... vials and painful needles to the modern-day ...
(Date:9/23/2014)... SAN FRANCISCO , Sept. 23, 2014  SiteOne ... round of equity financing. Led by Sears Capital Management ... and Joe Zakrzewski , the $1.5 million financing ... inhibitor program for pain and to further develop its ... other pain indications. In conjunction with the ...
(Date:9/23/2014)... September 23, 2014 According ... by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), ... Orthopedics) - Global Forecasts to 2019", published by ... forecast period of 2014 to 2019. The market ... at CAGR of 9.6% from 2014 to 2019. ...
Breaking Medicine Technology:Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4
... Oct. 12, 2011 Reportlinker.com announces that ... in its catalogue: ... Region 2010-2014 ... the Peripheral Vascular Devices market in the ...
... (NYSE: BSX ) will webcast its conference call ... 2011 on Thursday, October 20, at 8:00 a.m. ET. ... becomes Boston Scientific,s Chief Executive Officer on October 17, and ... A live webcast of the conference call will be ...
Cached Medicine Technology:Peripheral Vascular Device Market in the APAC Region 2010-2014 2Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... 5, that its Private Label Jalapeno Bagels are recalled ... stones. Publix Jalapeno Bagels were sold in ... department. , Taking into consideration the latest developments, ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- A test used to diagnose ... where certain lung infections are more common, a new analysis ... is through the use of what,s known as functional imaging. ... FDG-PET is used, according to the study authors. Cancerous ... parts of the lungs that don,t have cancer, according ...
(Date:9/23/2014)... Grinnell Mutual seeks submissions from the public ... Working Together Making It Better will provide grants ... positively impacting their communities. , “So many people ... a better places,” said Grinnell Mutual ... “Their leadership—as coaches, as volunteers, as mentors—help to ...
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ... allergic rhinitis (AR) is highly fragmented, with ... SIT formulations available, under different regulatory restrictions, ... markets. Europe has the most developed market, ... and allergen immunotherapy tablets (AITs) all being ...
Breaking Medicine News(10 mins):Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2Health News:Note to young men: Fat doesn't pay 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... and community for decades, PHILADELPHIA, Nov. 11 ... leading health insurer, turns 70,years old. While health ... 1938, experts agree that access to affordable,quality health ... was a key,consideration when millions cast their vote ...
... Introducing ReBound(TM) the Revolution in Thermotherapy, ALAMEDA, ... and,ReGear Life Sciences announced today the introduction of ... to treat pain, muscle,spasms, and joint contractures using ... for providing state-of-the-art injury treatment systems,to the physical ...
... triglycerides throughout the body , , TUESDAY, Nov. 11 (HealthDay ... the risk of high blood pressure in women who ... of a new study by U.S. researchers who analyzed ... Study. , Lipoprotein particles carry cholesterol and triglycerides throughout ...
... walls as thick as that of a middle-aged person ... days are 13 going on 45, at least when ... presented Tuesday at the American Heart Association,s annual scientific ... representative of someone three decades older. , "These data ...
... NEW YORK, Nov. 11 Today, the ... the results of a,nationwide survey on the ... "Unfortunately, APIC failed to connect the dots,",says ... to Reduce Infection,Deaths (RID). "The new data ...
... 11 Pam Kreager, Director of,Clinical Quality ... Term,Care Group, Inc. (LTCG), has been elected ... (LTCIF). The Long Term Care International Forum,( ... is to promote,efficiency, effectiveness and high standards ...
Cached Medicine News:Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 2Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 3Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 4Health News:Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 5Health News:Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market 2Health News:Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market 3Health News:Lipoprotein Levels May Predict Women's Hypertension Risk 2Health News:Obese Kids Have Old Arteries 2Health News:Obese Kids Have Old Arteries 3Health News:APIC Covers Up Extent and Causes of Deadly C. diff 2Health News:Long Term Care International Forum names LTCG's Pam Kreager as President 2
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... of both worlds, the PeaceKeeper 20 ... latest addition to the Wet-Field comprehensive ... instruments for ophthalmic surgery. Combining highly ... and backflush functionality in a single ...
...
...
Medicine Products: